Início > BIGG > Resultado da busca

    Resultados: 2

    The advisory committee on immunization practices’ interim recommendation for use of Pfizer-Biontech Covid-19 vaccine in children aged 5–11 years: United States, november 2021

    Woodworth, Kate R; Moulia, Danielle; Collins, Jennifer P; Hadler, Stephen C; Jones, Jefferson M; Reddy, Sujan C; Chamberland, Mary; Campos-Outcalt, Doug; Morgan, Rebecca L; Brooks, Oliver; Talbot, H. Keipp; Lee, Grace M; Bell, Beth P; Daley, Matthew F; Mbaeyi, Sarah; Dooling, Kathleen; Oliver, Sara E.
    MMWR recomm. rep; 70 (45), 2022
    The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Applicati...
    Vacina BNT162/imunologia, Vacina BNT162/uso terapêutico, Programas de Imunização/normas, COVID-19/prevenção & controle
    Texto completo

    Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices: United States, December 2021

    Oliver, Sara E; Wallace, Megan; See, Isaac; Mbaeyi, Sarah; Godfrey, Monica; Hadler, Stephen C; Jatlaoui, Tara C; Twentyman, Evelyn; Hughes, Michelle M; Rao, Agam K; Fiore, Anthony; Su, John R; Broder, Karen R; Shimabukuro, Tom; Lale, Allison; Shay, David K; Markowitz, Lauri E; Wharton, Melinda; Bell, Beth P; Brooks, Oliver; McNally, Veronica; Lee, Grace M; Talbot, H. Keipp; Daley, Matthew F.
    MMWR recomm. rep; 71 (3), 2022
    On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (A...
    Trombose/complicações, Ad26COVS1/efeitos adversos, Programas de Imunização/normas, COVID-19/prevenção & controle, Síndrome de Guillain-Barré/complicações
    Texto completo